39100222|t|Cardioprotective Effects of alpha-Asarone Against Hexavalent Chromium-Induced Oxidative Damage in Mice.
39100222|a|Introduction: This comprehensive study investigated the therapeutic potential of alpha-asarone in mitigating myocardial oxidative damage, primarily induced by hexavalent chromium (Cr(VI)) exposure in mice. Methods: In this experiment, 24 mice were divided into four groups to assess the cardioprotective role of alpha-asarone. The study focused on two treatment groups, receiving 25 mg and 50 mg of alpha-asarone, respectively. These groups were compared against a control group subjected to Cr(VI) without alpha-asarone treatment, and a normal control negative group. The key biochemical parameters evaluated included serum levels of Creatine Kinase-MB (CK-MB) and Troponin I, markers indicative of myocardial damage. Additionally, the levels of Malondialdehyde (MDA) were measured to assess lipid peroxidation, alongside the evaluation of key inflammatory biomarkers in cardiac tissue homogenates, such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1beta (IL-1beta). Results Remarkably, alpha-asarone treatment resulted in a significant reduction in these markers compared to the control group. The treatment also elevated the activity of cardinal antioxidant enzymes like catalase (CAT) and superoxide dismutase (SOD), and reduced the glutathione (GSH). Furthermore, a notable upregulation of Peroxisome Proliferator-Activated Receptor Gamma (PPAR-gamma) in cardiac tissue homogenates was observed, highlighting a potential pathway through which alpha-asarone exerts its protective effects. Histopathological analysis of cardiac tissues revealed that alpha-asarone ameliorated the structural lesions induced by Cr(VI). The study thus provides substantial evidence that alpha-asarone ameliorates Cr(VI)-induced cardiotoxicity through a multifaceted approach. It enhances cardiac enzyme function, modulates free radical generation, improves antioxidant status, and mitigates histopathological damage in cardiac tissues. Given these findings, alpha-asarone emerges as a promising agent against Cr(VI)-induced myocardial injury. Purpose: This study paves the way for further research into the cardioprotective properties of alpha-asarone and its potential application in clinical settings by specifically exploring the protective efficacy of alpha-asarone against Cr(VI)-induced cardiotoxicity and delineating the underlying biochemical and molecular mechanisms involved.
39100222	28	41	alpha-Asarone	Chemical	MESH:C012195
39100222	50	69	Hexavalent Chromium	Chemical	MESH:C074702
39100222	88	94	Damage	Disease	MESH:D020263
39100222	98	102	Mice	Species	10090
39100222	185	198	alpha-asarone	Chemical	MESH:C012195
39100222	213	240	myocardial oxidative damage	Disease	MESH:D004194
39100222	263	282	hexavalent chromium	Chemical	MESH:C074702
39100222	284	290	Cr(VI)	Chemical	MESH:C074702
39100222	304	308	mice	Species	10090
39100222	342	346	mice	Species	10090
39100222	416	429	alpha-asarone	Chemical	MESH:C012195
39100222	503	516	alpha-asarone	Chemical	MESH:C012195
39100222	596	602	Cr(VI)	Chemical	MESH:C074702
39100222	611	624	alpha-asarone	Chemical	MESH:C012195
39100222	804	821	myocardial damage	Disease	MESH:D009202
39100222	851	866	Malondialdehyde	Chemical	MESH:D008315
39100222	868	871	MDA	Chemical	MESH:D008315
39100222	897	902	lipid	Chemical	MESH:D008055
39100222	949	961	inflammatory	Disease	MESH:D007249
39100222	1012	1039	Tumor Necrosis Factor-alpha	Gene	7124
39100222	1041	1050	TNF-alpha	Gene	7124
39100222	1056	1073	Interleukin-1beta	Gene	3553
39100222	1075	1083	IL-1beta	Gene	3553
39100222	1106	1119	alpha-asarone	Chemical	MESH:C012195
39100222	1292	1300	catalase	Gene	847
39100222	1302	1305	CAT	Gene	847
39100222	1311	1331	superoxide dismutase	Gene	6647
39100222	1333	1336	SOD	Gene	6647
39100222	1355	1366	glutathione	Chemical	MESH:D005978
39100222	1368	1371	GSH	Chemical	MESH:D005978
39100222	1413	1461	Peroxisome Proliferator-Activated Receptor Gamma	Gene	5468
39100222	1463	1473	PPAR-gamma	Gene	5468
39100222	1566	1579	alpha-asarone	Chemical	MESH:C012195
39100222	1671	1684	alpha-asarone	Chemical	MESH:C012195
39100222	1712	1719	lesions	Disease	MESH:D009059
39100222	1731	1737	Cr(VI)	Chemical	MESH:C074702
39100222	1789	1802	alpha-asarone	Chemical	MESH:C012195
39100222	1815	1821	Cr(VI)	Chemical	MESH:C074702
39100222	1830	1844	cardiotoxicity	Disease	MESH:D066126
39100222	2011	2017	damage	Disease	MESH:D020263
39100222	2060	2073	alpha-asarone	Chemical	MESH:C012195
39100222	2111	2117	Cr(VI)	Chemical	MESH:C074702
39100222	2126	2143	myocardial injury	Disease	MESH:D009202
39100222	2240	2253	alpha-asarone	Chemical	MESH:C012195
39100222	2358	2371	alpha-asarone	Chemical	MESH:C012195
39100222	2380	2386	Cr(VI)	Chemical	MESH:C074702
39100222	2395	2409	cardiotoxicity	Disease	MESH:D066126
39100222	Negative_Correlation	MESH:C012195	MESH:D066126
39100222	Positive_Correlation	MESH:C074702	MESH:D066126
39100222	Positive_Correlation	MESH:C012195	5468
39100222	Positive_Correlation	MESH:C074702	MESH:D009202
39100222	Negative_Correlation	MESH:C012195	MESH:D009059
39100222	Positive_Correlation	MESH:C074702	MESH:D009059
39100222	Negative_Correlation	MESH:C012195	7124
39100222	Association	MESH:D007249	3553
39100222	Association	MESH:D007249	7124
39100222	Positive_Correlation	MESH:C074702	MESH:D004194
39100222	Negative_Correlation	MESH:C012195	3553
39100222	Positive_Correlation	MESH:C012195	6647
39100222	Negative_Correlation	MESH:C012195	MESH:D020263
39100222	Positive_Correlation	MESH:C012195	847
39100222	Negative_Correlation	MESH:C012195	MESH:D005978
39100222	Positive_Correlation	MESH:C074702	MESH:D020263
39100222	Negative_Correlation	MESH:C012195	MESH:C074702
39100222	Negative_Correlation	MESH:C012195	MESH:D004194

